<?xml version="1.0" encoding="UTF-8"?>
<p id="Par55">The PREOPANC-2 trial is a nationwide multicenter randomized phase III trial, conducted in 15 centers that provide multidisciplinary treatment for pancreatic cancer throughout the Netherlands. The study opened for accrual on June 5th, 2018. At the time of submission of this paper, all centers were actively recruiting and treating patients. A total of 294 patients were included in the trial on September 1st, 2020.</p>
